Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
$0.00
$0.00
▼
$0.00
N/AN/AN/A11,500 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$291.80
-1.6%		$246.06
$144.26
▼
$303.30
$13.92B1.38972,035 shs659,833 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%-1.16%+24.08%+61.17%+79.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
$0.00
$0.00
▼
$0.00
N/AN/AN/A11,500 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$291.80
-1.6%		$246.06
$144.26
▼
$303.30
$13.92B1.38972,035 shs659,833 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%-1.16%+24.08%+61.17%+79.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.69
Moderate Buy$255.65-12.39% Downside

Current Analyst Ratings Breakdown

Latest BUX and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$235.00 ➝ $300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$264.00
8/7/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$260.00 ➝ $300.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$291.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$215.00 ➝ $282.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Overweight$180.00 ➝ $310.00
8/5/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$300.00
8/5/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
7/20/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Hold$219.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.47$21.97 per share13.28$59.62 per share4.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A23.183.03-5.96%15.75%6.51%11/4/2026 (Estimated)

Latest BUX and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04

Institutional Ownership

CompanyInstitutional Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%

Insider Ownership

CompanyInsider Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable

Recent News About These Companies

James Foster Sells 33,561 Shares of Charles River Laboratories International (NYSE:CRL) Stock
August 29 at 4:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30990845
Zacks Research Has Pessimistic Outlook of CRL Q3 Earnings
August 29 at 2:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989632
Zacks Research Issues Positive Estimate for CRL Earnings
August 28 at 7:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-issues-positive-estimate-for-crl-earnings-2026-08-28/
Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 33,561 Shares
August 28 at 6:21 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-crl-insider-buying-and-selling-2026-08-28/
Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells 33,561 Shares of Stock
August 27 at 5:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-charles-river-laboratories-international-nyse-crl-director-sells-33561-shares-of-stock-2026-08-27/
Equities Analysts Offer Predictions for CRL Q3 Earnings
August 27 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-equities-analysts-offer-predictions-for-crl-q3-earnings-2026-08-27/
Medigen links up with Charles River in push to take enterovirus vaccine global
August 26, 2026  |  fiercebiotech.comF
Is Wall Street bullish or bearish on Charles River Laboratories stock?
August 26, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/is-wall-street-bullish-or-bearish-on-charles-river-laboratories-stock/ar-AA2aYT4h
Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week High - Here's Why
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-charles-river-laboratories-international-nyse-crl-reaches-new-52-week-high-heres-why-2026-08-25/
Charles River Labs and Medigen Vaccine collaboration
August 21, 2026  |  thepharmaletter.comT
Are options traders betting on a big move in Charles River stock?
August 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/are-options-traders-betting-on-a-big-move-in-charles-river-stock/ar-AA2aF3av
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
August 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2978367/crl-jumps-33-3-in-the-past-month-can-this-strong-rally-keep-running?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2978367
Charles River Gains 88.6% in a Year: What's Driving the Rally?
August 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2978284/charles-river-gains-88-6-in-a-year-what-s-driving-the-rally?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2978284
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-crl-insider-buying-and-selling-2026-08-21/
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madison-asset-management-llc-invests-381-million-in-charles-river-laboratories-international-inc-crl-2026-08-21/
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/charles-river-laboratories-international-nysecrl-director-nancy-andrews-sells-573-shares-2026-08-20/
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/shannon-parisotto-sells-2039-shares-of-charles-river-laboratories-international-nysecrl-stock-2026-08-20/
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/charles-river-laboratories-medigen-vaccine-120000683.html
How an Insider CEO Is Taking a Fresh Look at Charles River
August 20, 2026  |  wsj.comhttps://www.wsj.com/business/media/how-an-insider-ceo-is-taking-a-fresh-look-at-charles-river-6be8a215
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High - Here's Why
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/charles-river-laboratories-international-nysecrl-reaches-new-12-month-high-heres-why-2026-08-17/
Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-increases-stock-position-in-charles-river-laboratories-international-inc-crl-2026-08-15/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomark Diagnostics stock logo

Biomark Diagnostics CNSX:BUX

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$291.80 -4.61 (-1.56%)
As of 08/28/2026 03:58 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas